Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$0.76
--
Market closed
$0.76
--
Day’s Range― - ―
52-Week Range$0.69 - $2.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)473.32K
Market Cap
$64.93M
Enterprise Value$74.13
Total Cash (Recent Filing)$40.65M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Nov 06, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding86,267,030
10 Day Avg. Volume595,279
30 Day Avg. Volume473,316
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside689.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Fast Track DesignationFast Track status may accelerate FDA interaction and development of LTI-03, improving the program’s regulatory path and potential strategic value if clinical efficacy and safety are demonstrated.
Debt-Free Balance SheetNo debt limits leverage and interest obligations, giving Rein greater financial flexibility than a highly indebted biotech while it funds clinical development and seeks future financing or partnerships.
Reduced Operating LossThe narrower operating loss indicates some improvement in cost structure or spending discipline. Although Rein remains unprofitable, sustained control of expenses could extend its development runway before revenue begins.
Bears Say
Pre-Revenue Business ModelRein has no commercial revenue to offset research and development costs, leaving results dependent on clinical success, regulatory approval and future financing or licensing transactions.
Persistent Cash BurnContinued cash consumption creates funding risk and may require additional equity, partnerships or other capital before product revenue emerges. Financing needs could constrain development or dilute shareholders.
Nasdaq Delisting RiskFailure to restore compliance by February 17, 2027 could lead to suspension or delisting, potentially reducing investor access, impairing financing capacity and complicating the company’s ability to fund its pipeline.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.69 and its highest was $2.18 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $64.93M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 64 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.07.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 86,267,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 2.414%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (689.47% Upside)
$6.00 (689.47% Upside)
Blogger Sentiment
Bullish
RNTX Sentiment 100%
Sector Average 60%
Sector Average 60%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 21.0%
Last 30 Days ▼ 21.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.89%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Stock 12 Month Forecast
Average Price Target
$6.00
▲(689.47% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
XBiotech
―
Elicio Therapeutics
―
Xilio Therapeutics
―
Ownership Overview
1.76% Insiders
1.37% Mutual Funds
36.34% Other Institutional Investors
56.50% Public Companies and
Individual Investors